Abstract | BACKGROUND:
Keloids are characterized by benign proliferation of fibroblasts in the setting of an altered cytokine profile, with a high recurrence rate after surgical treatment. Imiquimod is a topically applied immune-response modifier. Recently, auxiliary therapy using imiquimod 5% cream to prevent keloid recurrence after excisional surgery was reported to have had good results. OBJECTIVE: To evaluate the efficacy of topical imiquimod 5% cream applied after surgical excision and primary closure of trunk keloids in the prevention of recurrence. METHOD: Nine patients with a keloid lesion on the trunk were treated with surgical excision and primary closure. Daily application of imiquimod 5% cream for 8 weeks was initiated the night of surgery. The patients were evaluated 2, 4, 8, 12, and 20 weeks after. RESULTS:
Keloid recurrence occurred in eight patients, seven of them 12 weeks after surgery. We lost track of one patient. CONCLUSION: The results of this study suggest that imiquimod 5% cream is not effective in preventing recurrence of trunk keloids after surgical excision. Although this is a small case series, results strongly discourage other studies using imiquimod 5% cream in the prevention of surgically excised trunk keloids.
|
Authors | Fernanda Marson Cação, Vanessa Tanaka, Maria Cristina de Lourenzo Messina |
Journal | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
(Dermatol Surg)
Vol. 35
Issue 4
Pg. 629-33
(Apr 2009)
ISSN: 1524-4725 [Electronic] United States |
PMID | 19415792
(Publication Type: Journal Article)
|
Chemical References |
- Adjuvants, Immunologic
- Aminoquinolines
- Emollients
- Imiquimod
|
Topics |
- Adjuvants, Immunologic
(administration & dosage)
- Administration, Topical
- Adult
- Aminoquinolines
(administration & dosage)
- Emollients
- Female
- Humans
- Imiquimod
- Keloid
(drug therapy, surgery)
- Male
- Middle Aged
- Secondary Prevention
- Treatment Outcome
- Young Adult
|